Cisspect NKI Analyse #2

Which patients will respond to cisplatin chemotherapy?


Being able to predict which cancer patient is likely to respond to chemotherapy with cisplatin has not yet been possible. However, a unique collaboration between NRG|PALLAS, the Netherlands Cancer Institute and Amsterdam UMC may bring about some change. By administering 195mPlatinum radiolabeled cisplatin to cancer patients, researchers aim to assess which patients will respond to therapy and who will not benefit and thus may not be given this treatment.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.